Navigation Links
Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
Date:5/20/2008

SAN DIEGO, May 20 /PRNewswire-FirstCall/ -- A post hoc analysis showing time to symptom resolution data from a study (study 302) of Shire plc's (LSE: SHP, Nasdaq: SHPGY) ulcerative colitis (UC) drug, LIALDA(TM), will be presented today at Digestive Disease Week (DDW). Study 302 (further referred to as "Kamm study," led by Dr Michael A. Kamm, from St Mark's Hospital in London, UK), demonstrated LIALDA was effective in inducing remission in patients with active, mild to moderate ulcerative colitis compared to placebo and these study results were published in the January 2007 issue of Gastroenterology.

"The time between initiation of therapy and initial symptom resolution is an important endpoint in the treatment of UC for both patients and physicians," said Gary Lichtenstein, director of the Inflammatory Bowel Disease Program at the University of Pennsylvania, investigator on this post hoc analysis. "This analysis was important as it showed LIALDA benefits patients by significantly lowering the time it takes patients to experience relief from their UC symptoms as compared to placebo."

Time to initial symptom resolution on LIALDA

Poster Presentation: May 20, 2008, San Diego Convention Center -- Sails Pavilion, #T1140

A post hoc analysis of the Kamm study (study 302) examined the treatment time required for patients to experience initial symptom resolution over eight weeks. In this analysis, time to initial symptom resolution was assessed as either the time between the first dose of study medication and the first day of symptom resolution (rectal bleeding or normalization of stool frequency or both) or the time between the first dose of study medication and the first day of three consecutive days of symptom resolution. Initial symptom resolution of rectal bleeding, normalization of stool frequency or both was assessed by a modified UC-Disease Activity Index (UC-DAI) scoring system. Resolution of symptoms was defined for both rectal ble
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 5, 2015 Faced with fast economy and population ... China,s medical device industry has been ... largest demands have been Beijing , ... other first-tier cities. However, the entry of a large number ... "high-end" markets in first-tier cities increasingly saturated. How do medical ...
(Date:5/5/2015)... , May 05, 2015 Research and ... the addition of the "Clinical Laboratory,Molecular Diagnostics ... 2015 to 2019 - Latin America, Africa and ... A market that just keeps on ... benefit from the explosion in biotechnology, especially genomics. ...
(Date:5/5/2015)... Colo. , May 5, 2015  As cannabis prohibition ends one state at a time, more cannabis entrepreneurs are coming ... the idea phase, and the primary reason is lack of funding. ... ... ... ...
Breaking Medicine Technology:MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 2MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 3MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 4Latin America, Africa and Middle East Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019 2Top Ten Ways Cannabis Startups are Getting Funded 2Top Ten Ways Cannabis Startups are Getting Funded 3Top Ten Ways Cannabis Startups are Getting Funded 4
... Astellas Pharma Inc. (Tokyo:4503, "Astellas") announced today that ... 1] , which will further reinforce the company,s commitment to ... world. "We are committed to adopting the Global ... culture and day-to-day operations of our company and through Astellas, ...
... 2011 Watson Pharmaceuticals, Inc. (NYSE: WPI ... filed an Abbreviated New Drug Application (ANDA) with the ... market rivastigmine transdermal system patches, 4.6 mg/24 hr and ... a generic version of Novartis, Exelon(R) Patch. Exelon(R) is ...
Cached Medicine Technology:Astellas Signs United Nations Global Compact 2Astellas Signs United Nations Global Compact 3Watson Confirms Exelon(R) Patent Challenge 2Watson Confirms Exelon(R) Patent Challenge 3
(Date:5/5/2015)... AZ (PRWEB) May 05, 2015 NCPDP ... Elite Partner Program. The program establishes a three-year commitment ... a maximum of 10 Elite Partners. “AmerisourceBergen has supported ... Stember, President of NCPDP, “and this is a wonderful ... , We can trace AmerisourceBergen back to our ...
(Date:5/5/2015)... Leveraging the industry-leading technology found at ... experienced team of fertility specialists are committed to the ... the globe. , “We’re honored that Maternity Health IVF ... global leader in reproductive medicine. The clinic offers some ... the world who play an important role in the ...
(Date:5/5/2015)... York (PRWEB) May 05, 2015 ... http://www.testosteronelawsuithub.com/ ) filed on behalf of men ... to their use of prescription testosterone replacement ... federal multidistrict litigation underway in U.S. District ... court documents dated May 1st, defendants AbbVie, ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Baptist Medical ... Commission on Cancer (CoC) of the American College of ... program must meet more than 30 Commission on Cancer ... a survey process, and maintain levels of excellence in ... When patients choose to seek care locally at a ...
(Date:5/5/2015)... Georgia (PRWEB) May 05, 2015 ... of Victoria BC announced the Skedans Sensor Collaboration ... platform, for mobile and web app developers, provides tooling ... airborne and mobile sensors. , The Skedans Sensor Collaboration ... the intersection of the Internet of Things, Web Real ...
Breaking Medicine News(10 mins):Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 3Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 2Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2
... could lead to new drugs in fight against obesity, study ... produced in the brain may play a role in regulating ... new study. , For the study, researchers looked at ... genetic condition that occurs in one in 500,000 to a ...
... to standard drug therapy prolonged survival, study finds , , ... myeloma who could not tolerate high dose chemotherapy lived ... standard treatment, a new study found. , The finding ... plasma cells, a chronic rather than a lethal disease. ...
... form of the eye disease , , WEDNESDAY, Aug. 27 ... China have identified the first gene directly associated with ... two forms of age-related macular degeneration that currently threatens ... , The discovery, based on work with both human ...
... COLUMBUS, Ga., Aug. 27 Aflac Incorporated,(NYSE: AFL ... at the Keefe,Bruyette & Woods 2008 Insurance Conference. President ... Incorporated, and he is,scheduled to make a presentation on ... Incorporated presentation, Mr. Cloninger will discuss the,company,s outlook for ...
... with unlawful changes in wages and benefits, HEMET, Calif., ... Monday issued a complaint against the,board of directors of Valley ... that the board had already voted to agree to., ... not for the money," said,Lisa Howell, a registered nurse at ...
... or not,women and men have different oral health needs. ... throughout their life, including,puberty, pregnancy and menopause., The ... evolving oral health needs will ensure that everyone,regardless of ... health care they,need to maintain healthy teeth and gums., ...
Cached Medicine News:Health News:Low Levels of Brain Chemical May Control Appetite 2Health News:Combination Therapy Helps to Combat Myeloma 2Health News:Combination Therapy Helps to Combat Myeloma 3Health News:Gene Linked to 'Dry' Macular Degeneration 2Health News:Gene Linked to 'Dry' Macular Degeneration 3Health News:Aflac Incorporated To Present at the Keefe, Bruyette & Woods 2008 Insurance Conference 2Health News:State Board Issues Complaint: VHS Board Should Have Signed Contract With Caregivers 2Health News:What You Need to Know About Women's Oral Health 2
... The U.S. Food and Drug Administration ... ReSTOR intraocular lens (IOL) for cataract patients ... uses a revolutionary apodized diffractive technology to ... vision (near, intermediate and distance) that greatly ...
... for quality vision with ACRYSOF IQ IOL. ... aberration by addressing the effects of over-refraction ... increasing edge thickness. Human corneal characteristics ... provides improved image quality.,MTF (measured in the ...
... find the samaritan AED easy to ... and rescue professionals) will appreciate the ... override, and the ECG monitoring availability ... is an exceptionally well-engineered, lightweight (4lbs), ...
... The Brilliance 64-channel configuration breaks through ... large volume, thin-slice coverage to improve ... , ,With 40mm of thin-slice coverage, ... imaging, allowing for unprecedented coronary artery ...
Medicine Products: